Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRAS G12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies

Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRAS G12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies

Abstract IBI351 (also known as fulzerasib or GFH925), an irreversible covalent inhibitor of KRASG12C, has demonstrated promising anti-tumour activity in patients with solid tumours. In this study, data were pooled from the phase I part of two clinical studies (NCT05005234 and NCT05497336), aiming to...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Yuan, Yanhong Deng, Yongdong Jin, Zengqing Guo, Yueyin Pan, Cunji Wang, Zhiwu Wang, Yi Hu, Dong Hua, Xiangjiao Meng, Zhiye Zhang, Mingfang Zhao, Xiaorong Dong, Dingzhi Huang, Xiaoyan Li, Lian Liu, Meili Sun, Huijuan Wang, Xiuwen Wang, Nong Yang, Mingjun Zhang, Sheng Hu, Dongde Wu, Jingjing Huang, Sujie Zhang, Mengna Huang, Kefeng Ding
Format: Article
Language:English
Published: Nature Publishing Group 2025-07-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02315-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-025-02315-7

Similar Items